The oral weight-loss drug battle has begun, with Roche's Novo Nordisk and Novo Nordisk vying for a market of about 5 billion US dollars in the first year.

The second day after the oral weight loss drug Orforglipron from Novo Nordisk was approved by the US FDA for listing, it was learned that Novo Nordisk has currently conducted 7 phase III clinical studies on Orforglipron for obesity and type 2 diabetes, with a total of over 10,000 patients enrolled globally, including Chinese patients participating in 6 global multicenter studies.